Preclinical research is underway for NPI 32101 in the area of gastrointestinal (GI) diseases. There are large markets with unmet needs in a spectrum of diseases characterized by inflammation and ulceration of the lining of the colon.
NUCRYST's first focus in gastrointestinal diseases is ulcerative colitis. Research is in early stages of development. Early preclinical testing demonstrated that nanocrystalline silver (NPI 32101) suppresses colonic inflammation in several preclinical models of ulcerative colitis and is as effective as sulfasalazine. These data were presented at the October 2006 meeting of the American College of Gastroenterologists (ACG).
NUCRYST has repeatedly demonstrated a dose response with various NPI 32101 formulations. Advancing the ulcerative colitis program is a key strategy for 2007.
While pursuing ulcerative colitis, NUCRYST identified another important and growing GI disease, Clostridium difficile-associated disease (CDAD). Early in vitro data has shown promising results for both vegetative and spore forms of C. difficile.